Baidu
map

CFDA公布6项医疗器械行业标准, 2018年12月1日起实施

2017-12-13 佚名 新浪医药

12月11日,食品药品监管总局发布公告称,YY/T 0588—2017《流式细胞仪》、YY/T 1591—2017 人类EGFR基因突变检测试剂盒等6项医疗器械行业标准已经审定通过,予以公布。标准自2018年12月1日起实施。

12月11日,食品药品监管总局发布公告称,YY/T 0588—2017《流式细胞仪》、YY/T 1591—2017 人类EGFR基因突变检测试剂盒等6项医疗器械行业标准已经审定通过,予以公布。标准自2018年12月1日起实施。

标准编号、名称如下:

YY/T 0588—2017 流式细胞仪

YY/T 1585—2017 总25-羟基维生素D测定试剂盒(标记免疫分析法)

YY/T 1591—2017 人类EGFR基因突变检测试剂盒

YY/T 1595—2017 氯胺酮检测试剂盒(胶体金法)

YY/T 1596—2017 甲型流感病毒核酸检测试剂盒(荧光PCR法)

YY/T 1597—2017 新生儿苯丙氨酸测定试剂盒

附:

YY/T 0588—2017《流式细胞仪》等6项医疗器械行业标准适用范围

一、YY/T 0588—2017《流式细胞仪》

本标准规定了流式细胞仪(Flow Cytometer,FCM)的术语和定义、产品分类、技术要求、试验方法、标志、标签和使用说明、包装、运输和贮存。本标准适用于临床使用的对单细胞或其他非生物颗粒膜表面以及内部的生物化学及生物物理特性成分进行定量分析和分选(只限于有分选功能的流式细胞仪)的流式细胞仪。本标准代替YY/T 0588—2005《流式细胞仪》。

二、YY/T 1585—2017《总25-羟基维生素D测定试剂盒(标记免疫分析法)》

本标准规定了人总25-羟基维生素D测定试剂盒(标记免疫分析法)的分类、要求、试验方法、标识、标签、使用说明书、包装、运输和贮存。本标准适用于定量测定人总25-羟基维生素D的试剂盒。包括以酶标记、(电)化学发光标记等标记方法为捕获抗体,以微孔板、管、磁颗粒、微珠和塑料珠等载体为包被抗体,用于体外定量检测人血清或血浆中总25-羟基维生素D的含量的免疫分析试剂盒。本标准不适用于用胶体金或其他方法标记的定性或半定量测定人总25-羟基维生素D的试剂(如:试纸条、生物芯片等),以及拟用于单独销售的25-羟基维生素D校准品和25-羟基维生素D质控品。

三、YY/T 1591—2017《人类EGFR基因突变检测试剂盒》

本标准规定了人类表皮生长因子受体(Human Epidermal growth factor Receptor,EGFR)基因突变检测试剂盒的要求、试验方法、标签和使用说明书、包装、运输和贮存。本标准适用于肿瘤组织或者细胞石蜡包埋切片、新鲜冰冻肿瘤组织提取的DNA样本中EGFR基因突变检测,外周血(浆)中EGFR基因突变检测可参照并制定符合外周血(浆)中EGFR基因突变检测所需的技术要求。本标准适用于定性检测人类EGFR基因突变,采用的技术方法有荧光PCR法、流式荧光杂交法、荧光PCR熔解曲线法、焦磷酸测序法和Sanger测序法等。本标准不适用于检测EGFR基因拷贝数变化的荧光原位杂交法;也不适用于检测EGFR基因突变的高通量测序法。

四、YY/T 1595—2017《氯胺酮检测试剂盒(胶体金法)》

本标准规定了氯胺酮检测试剂盒(胶体金法)标准的术语和定义、要求、试验方法、标识、标签、使用说明书及包装、运输和贮存等。本标准适用于通过胶体金免疫层析法原理,定性检测人体尿液中氯胺酮(Ketamine,KET)的检测试剂盒及包含氯胺酮的联合检测试剂盒。本标准不适用于进行非人尿液检测的检测试剂盒,以及采用其他方法检测的试剂盒。

五、YY/T 1596—2017《甲型流感病毒核酸检测试剂盒(荧光PCR法)》

本标准规定了甲型流感病毒核酸检测试剂盒(荧光PCR法)的术语和定义、要求、试验方法、标签和说明书,以及包装、运输和贮存。本标准适用于以荧光PCR法为原理,定性检测人鼻、咽拭子或其他呼吸道分泌物样本中甲型流感病毒核酸的试剂盒。本标准不适用于以恒温扩增法为原理,定性检测人鼻、咽拭子或其他呼吸道分泌物样本中甲型流感病毒核酸的试剂盒。

六、YY/T 1597—2017《新生儿苯丙氨酸测定试剂盒》

本标准规定了新生儿苯丙氨酸定量测定试剂盒的技术要求、试验方法、标识、标签、说明书、包装、运输和贮存等。本标准适用于定量检测新生儿脐血或足跟滤纸干血片样本的试剂盒,采用的技术方法有荧光法、酶法等。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890682, encodeId=a63c189068250, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 19 17:42:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269127, encodeId=82f626912e7d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Wed Dec 13 13:26:19 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269099, encodeId=84062690995b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 13 12:35:59 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269092, encodeId=dda426909228, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Dec 13 11:07:23 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2018-04-19 stfoxst
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890682, encodeId=a63c189068250, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 19 17:42:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269127, encodeId=82f626912e7d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Wed Dec 13 13:26:19 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269099, encodeId=84062690995b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 13 12:35:59 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269092, encodeId=dda426909228, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Dec 13 11:07:23 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-13 执着追梦

    学习.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1890682, encodeId=a63c189068250, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 19 17:42:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269127, encodeId=82f626912e7d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Wed Dec 13 13:26:19 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269099, encodeId=84062690995b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 13 12:35:59 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269092, encodeId=dda426909228, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Dec 13 11:07:23 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-13 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1890682, encodeId=a63c189068250, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 19 17:42:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269127, encodeId=82f626912e7d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Wed Dec 13 13:26:19 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269099, encodeId=84062690995b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 13 12:35:59 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269092, encodeId=dda426909228, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Dec 13 11:07:23 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-13 戒馋,懒,贪

    谢谢分享学习了

    0

Baidu
map
Baidu
map
Baidu
map